CoreWeave Principal Accounting Officer Sells 6,455 Shares Valued at ~$430K to Cover Tax Obligations
Jeff Baker, CoreWeave (NASDAQ:CRWV) principal accounting officer, reported selling 6,455 shares of Class A Common Stock on July 29, 2026. The transaction, valued at approximately $430,000 based on a weighted average sale price of $66.51 per share, was non-discretionary and executed solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following the sale, Baker retains direct ownership of 7,167 shares and holds 100,000 derivative securities.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
WASM: An In-Depth Look at WebAssembly Technology and a Guide to Trading Related Tokens ZKWASM and WASM AI
-
9
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
10
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
Markets Today
Recommended Reading








